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Transgenic mice carrying the entire polyomavirus (Py) early region consistently develop both vascular and
bone tumors. This tumor spectrum represents a subset of the tumors found in mice infected with Py and an
expansion of the vascular tumor spectrum seen in Py middle T antigen (MT) transgenic mice (V. L. Bautch,
S. Toda, J. A. Hassell, and D. Hanahan, Cell 51:529-538, 1987). Transgenic mice of three independent lineages
develop these pathologies, and mice of individual lineages also develop lymphangiomas and fibrosarcomas. All
tumors are of mesenchymal origin, and all tumor tissues express the Py transgene. Some unaffected tissues,
including the testes of mice of all lineages, also express the Py transgene. The number of transgene expression
sites in mice of a given lineage correlates with the severity and latency of the tumor phenotype in these animals.
Analysis of transgene transcripts indicates that RNAs for Py large T antigen (LT), MT, and small T antigen
(ST) are present in both tumors and testes of transgenic mice. The ratio of LT RNA to MT and ST RNAs,
however, is higher in testes than in tumors and other unaffected tissues, indicating that tissue-specific
differences in the relative amounts of the alternatively spliced Py RNAs exist. The finding that some sites of Py
transgene expression are susceptible to tumor formation while other expressing tissues such as testes are
refractory to tumorigenesis suggests that mechanisms of viral pathogenesis are influenced by a tissue specificity
in the effects of the Py early region.
Viral pathogenesis is a complex process involving virus-
host cell interactions that can lead to tumor formation (37).
One classic model for the study of viral pathogenesis is the
interactions of polyomavirus (Py) with its natural host, the
mouse (for reviews, see references 13 and 19). Py causes
tumors in a range of tissues in newborn and immunocom-
promised mice. The tumor spectrum of Py includes epithelial
tumors such as parotid gland tumors and mammary adeno-
carcinomas as well as mesenchymal tumors such as osteo-
sarcomas and fibrosarcomas (for a review, see reference 9).
Recently, viral strain differences in the tumor spectrum of Py
were documented, and the Py strains fit two broad catego-
ries: (i) epithelial and mesenchymal tumors and (ii) mesen-
chymal tumors only (10, 16).
The tumorigenic potential of Py is localized to the early
region of the Py genome that encodes three different gene
products (6). These proteins are translated from a single
primary transcript via alternative splicing (38). Py large T
antigen (LT) is a 100-kDa protein required for viral replica-
tion, Py middle T antigen (MT) is a 56-kDa protein with
transforming activity (24, 39), and Py small T antigen (ST) is
a 22-kDa protein that promotes growth in some assays (28).
Cell culture experiments have shown that Py LT is also
capable of immortalizing primary cells to continuous growth
in culture (32) and that Py MT can confer a transformed
phenotype to cultured cells. Moreover, these proteins can
cooperate with each other and with other oncogenes to fully
transform primary cells in culture (31, 33). Thus, Py provides
a convenient system for studying both the separate and the
concerted actions of viral oncogenes in vivo.
Studies of oncogene action in transgenic mice have shown
that both viral and cellular oncogene expression is correlated
with tumor formation and that many oncogenes show a
cell-type specificity in their action in vivo (for reviews, see
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references 7, 21, and 22). Surprisingly, a number of papova-
virus early regions that show a broad spectrum of expression
in cell culture have a restricted expression and tumor profile
in transgenic mice. For example, simian virus 40 early region
expression is restricted to a few tissue sites and leads to
predominantly choroid plexus tumors (5, 29). Likewise, the
JC virus and BK virus early regions show restricted expres-
sion in transgenic mice, leading to tumors that recapitulate
their tropism in humans (36). A Py early region promoter and
enhancer linked to a reporter gene showed low-level expres-
sion in a number of tissues (25).
To study the effects of the Py early region oncogenes in
vivo, we have generated transgenic mice carrying Py early
region cDNAs linked to the Py early region regulatory
sequences. Transgenic mice carrying the Py MT cDNA
showed restricted expression patterns and developed vascu-
lar endothelial cell tumors exclusively, transgenic mice
carrying the Py LT cDNA developed pituitary tumors with a
long latency, and transgenic mice carrying the Py ST cDNA
developed no detectable pathology (2, 2a, 3). Here we report
that transgenic mice carrying an intact Py early region that is
replication defective consistently develop vascular and bone
tumors, and with some frequency they also develop lym-
phangiomas and fibrosarcomas. These tumors are of mesen-
chymal-cell origin, and they represent an expanded tumor
spectrum relative to that of Py cDNA-carrying mice.
MATERIALS AND METHODS
DNA constructions. The Py DNA was of the Al strain (30),
and it has been modified from the wild-type genome as
described elsewhere to make Px13 DNA (3). Briefly, the Py
genome was linearized at the BamHI site in the late region
and inserted into the pML2 vector (26). The features of this
construct include a 23-bp deletion and an insertion of a XhoI
linker at nucleotides 37 to 60 that deletes a Py LT binding
site and makes the Py DNA replication defective. A ClaI
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FIG. 1. Py early region transgenic DNA. The baseline shows replication-defective Py DNA with bp 37 to 60 deleted and replaced by a XhoI
linker, bp 152 to 154 deleted and replaced with a ClaI linker, and a deletion of approximately 500 bp in the late coding sequences. Wavy line,
plasmid vector sequences; open box, late region DNA; dotted box, early region enhancer; diagonally striped box, early region DNA;
parentheses, deleted sequences. The upper lines show the Py early region transcripts from the transgene. Straight line, RNA; filled boxes,
protein-coding sequences; broken line, intron sequences. Immediately above the RNAs are wavy lines with arrows and numbers that denote
the locations of PCR primers relative to the map, and above those is a hatched box (PxXP64) that shows the location of the probe sequences
used for RNA protection.
linker was inserted at the transcriptional start site (nucleo-
tides 152 to 154), and a deletion of approximately 500 bp in
the late region prevents production of late region proteins.
PxXP64 was constructed by inserting the 424-bp XhoI-Pstl
restriction fragment of Px13 into SP64 in the antisense
direction relative to the SP6 promoter.
Generation and identification of transgenic mice. Px13
DNA was linearized at a Sail site in the plasmid sequences,
extracted with phenol and chloroform, ethanol precipitated,
and suspended in injection buffer as described elsewhere (3).
Microinjection was into F2 embryos from a mating of
B6D2F1 mice, and all procedures were as described previ-
ously (23) with modifications (3). Positive offspring were
identified by Southern blot analysis of genomic DNA ex-
tracted from tail clips and hybridized to 32P-labeled nick-
translated Px13 DNA as described previously (1, 3). Positive
mice were mated with B6D2F1 mice to establish germ line
transmission. Subsequent matings of positive transgenic
mice were usually male transgenic mice to B6D2F1 females,
and positive offspring were identified by dot blot analysis as
described elsewhere (35).
RNA isolation and analysis. Total RNA was isolated from
mouse organs by a modification of the hot-phenol method
(35) as described before (3). The RNA protection assay was
performed by a modification of a previously described
method (27). A 32P-labeled antisense RNA probe was syn-
thesized from PxXP64 DNA with SP6 polymerase. The
probe was hybridized with 10 or 20 ,ug of total RNA from
mouse tissues, and the mixture was digested with RNases A
and T1. The protected RNA products were analyzed by 8 M
urea-5% polyacrylamide gel electrophoresis and autoradiog-
raphy as described previously (3). The polymerase chain
reaction (PCR) was performed by a modification of the
method described by Saiki et al. (34). cDNA was synthe-
sized from total RNA as described elsewhere (17) with
modifications. A 10-,ug volume of total RNA and 1 ,ug of
oligonucleotide Px2 primer were combined in a total volume
of 14 p,l of H20 and heated to 75°C. After being cooled to
room temperature, a solution was made of 50 mM Tris (pH
8.3 at 42°C), 6 mM MgCl2, 40 mM KCl, 1 mM dithiothreitol,
2.5 mM each deoxynucleoside triphosphate, 1 U of RNAsin
per p,l, and 0.5 U of avian myeloblastosis virus reverse
transcriptase per p,l. After incubation at 42°C for 2 h, the
reaction mixture was used for the PCR reaction or stored at
-20°C. The PCR reaction contained 10 mM Tris (pH 8.4 at
room temperature), 50 mM KCl, 1.5 mM MgCl2, each
deoxynucleoside triphosphate at 200 ,uM, each Px oligonu-
cleotide at 0.01 ,ug/ul, 0.1% Triton X-100, and 0.03 U of Taq
polymerase (Promega Scientific) per Rll in a total volume of
100 ,u. A 2-RId volume of the cDNA mixture was added, and
the reaction mixture was overlaid with mineral oil. The
conditions for PCR with Px oligonucleotides 5 and 8 were
92°C for 10 s and 72°C for 2 min (30 cycles), and the
conditions for PCR with Px oligonucleotides 2 and 3 were
93°C for 10 s, 55°C for 2 min, and 72°C for 3 min (30 cycles).
RESULTS
Generation of transgenic mice. To determine the effects of
the Py early region gene in transgenic mice, the linearized Py
early region DNA illustrated in Fig. 1 was microinjected into
mouse embryos. The features of this construct include a
deletion of bp 37 to 60 and an insertion of a XhoI linker to
make the DNA replication defective, a deletion of bp 152 to
154 and an insertion of a ClaI linker, and a deletion of
approximately 500 bp in the late region to prevent produc-
tion of late region proteins. Colinear DNA constructs with
the same modifications and encoding Py LT or MT cDNAs
show expression in transgenic mice (2, 3).
Microinjection of Px13 DNA linearized with SalI into
fertilized one-cell mouse embryos produced 44 pups. Eight
of these pups (18%) were transgenic by Southern blot
analysis of genomic tail DNA extracted from biopsy speci-
mens taken from 2-week-old mice (data not shown). As
documented in Table 1, five (62.5%) of the eight transgenic
founder mice developed pathology that was fatal either at an
early age (e.g., mouse 267 died at 2.5 months) or at a later
age (e.g., mouse 268 died at 6 months). The documented
pathology in the founder mice was predominantly that of
vascular hemangiomas and bone tumors. Two founders
(Py-2 and Py-4), however, developed lymphangiomas, tu-
mors of the endothelial cells that line the lymph nodes.
Three of the founder mice, Py-6, Py-7, and Py-8, did not
develop any detectable pathology. Both the Py-6 and Py-7
founders were females who died at a relatively early age and
were gravid at death, so these mice possibly succumbed to
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TABLE 1. Pathology of Py transgenic founder mice
Founder Mouse no. Sexa Pathologyb Life span (mo)' Transmission % Transmission
Py-1 164 F Hemangioma 3.75 (S) 0/13 0
Py-2 256 F Lymphangiomas, osteosarcomas (skull, spine) 6.0 (S) 0/26 0
Py-3 257 M Hemangiomas 9.0 (D) 2/113 1.8
Py-4 267 M Hemangiomas, lymphangiomas, osteosarcoma 2.5 (D) 10/27 37.0
Py-5 268 F Hemangioma, osteosarcoma 6.0 (S) 24/39 61.5
Py-6 269 F NAD 2.0 (D) 0/7 0
Py-7 270 F NAD 1.75 (D) 0/9 0
Py-8 271 F NAD >12 (S) 0/41 0
a F, female; M, male.
b NAD, no abnormalities detected.
D, died; S, sacrificed. All mice sacrificed, except mouse 271 (Py-8), were moribund.
d Number of positive progeny/total number tested.
complications of pregnancy. The short life span of these
founders may have precluded the development of detectable
pathology resulting from the presence of the Py transgene.
The Py-8 founder was fertile and lived to an old age, but she
did not transmit the transgene to her progeny. Thus, she
most likely did not carry the Py transgene in every cell, and
this mosaicism may have affected transgene expression and
consequent lack of tumor development. In addition, the
transgene chromosomal integration site may have prevented
transgene expression and the consequent lack of pathology
in one or more of this subset of Py founder mice.
Three of the eight founder mice transmitted the Py trans-
gene to progeny, and the transmission ratios indicate that the
Py-3 founder mouse was mosaic for the transgene in his germ
line while the other two founder mice were probably heter-
ozygous for the transgene. Two founders with pathology,
Py-1 and Py-2, were probably mosaic because they died
without transmitting the transgene to progeny. However, all
of the founders that transmitted the transgene developed
pathology. All three of these founder mice developed vas-
cular hemangiomas, while two of three founders developed
bone tumors and one of three founders developed lymphan-
giomas (Table 1).
Pathology of Py transgenic mouse lineages. The three
lineages Py-3, Py-4, and Py-5 were derived from the three
founder Py transgenic mice that transmitted the transgene to
offspring, and their characteristics are documented in Table
2. In general, the pathology of progeny was similar to the
pathology of the respective founder mouse, although some
differences were noted. For example, examination of multi-
ple progeny showed the presence of bone tumors in Py-3
mice and the occasional presentation of a fibrosarcoma in
Py-3 and Py-5 mice. Transgenic mice of all lineages devel-
oped pathology that was eventually fatal to the animal, and
there were both similarities and differences among the phe-
notypes of the three lineages. Mice of all lineages developed
vascular and bone tumors, indicating that this tumor profile
TABLE 2. Pathology of Py transgenic mouse lineages
Lineage span (mo) Pathology
Py-3 6.9 Osteosarcoma, fibrosarcoma (rare), hemangi-
oma (rare)
Py-4 2.3 Osteosarcoma, hemangioma, lymphangioma
Py-5 7.2 Osteosarcoma, fibrosarcoma (rare), hemangi-
oma (rare)
aCalculated from 15 to 20 mice that died or were sacrificed when moribund.
is specific to the transgene and is not a position effect of the
chromosomal integration site. There were differences, how-
ever, in the complete tumor spectrum of the lineages. Mice
of the Py-4 lineage consistently developed lymphangiomas,
and mice of the other lineages never had this type of tumor.
Likewise, mice of the Py-3 and Py-5 lineages occasionally
developed fibrosarcomas, and mice of the Py-4 lineage never
had this tumor. Another striking difference was in the
average life span of the three lineages: Py-4 mice had an
extremely short average life span of 2.3 months, while Py-3
and Py-5 mice lived much longer, averaging 6.9 and 7.2
months, respectively.
The Py-4 transgenic mice presented a consistent set of
symptoms and pathological profile at sacrifice or necropsy.
They often showed visible signs of lymphangioma formation
at 4 to 6 weeks of age, and they quickly developed large
cystlike structures in the inguinal and axial areas. At approx-
imately 8 to 12 weeks of age, multiple small blood-filled
structures became visible on the ears, tail, and paws. These
mice became moribund several days prior to death, although
the exact cause of death was not determined. At necropsy,
all Py-4 mice showed multiple large cysts filled with a
straw-colored liquid at various sites including inguinal, axial,
cervical, retroperitoneal, and subcutaneous sites (Fig. 2C).
These cysts were sometimes intimately associated with
blood-filled cystic structures. Most mice showed evidence of
multiple small blood-filled structures on the ears and tail
(Fig. 2A), and males had small blood-filled areas on the
testes that resembled vascular tumors. In general, the blood-
filled tumors were not found at other sites in Py-4 mice. All
Py-4 mice also had an obvious thickening of the skull that
gave it a white, solid appearance rather than a thin, opales-
cent appearance (Fig. 2B).
Py-3 and Py-5 transgenic mice showed a less consistent,
less dramatic set of symptoms than did Py-4 mice. Mice of
these lineages usually developed a single tumor, and the
tumors were vascular, bony, or fatty. Mice with vascular
tumors usually had a tumor in one or two of several sites that
included most organs. The tumors most often were larger
than the blood-filled sacs of the Py-4 mice and in both
appearance and location resembled the hemangiomas of Py
MT mice (3). A subset of mice of both lineages developed
hind-limb paralysis at some point. Although tumors were not
detected macroscopically in all mice with this symptom, in
about 80% of these mice, tumors were found at autopsy, and
they were always bony tumors associated with the lower
spinal cord (Fig. 2D). Thus, the hind-limb paralysis is
probably a result of spinal-cord pinching by the bone tumors.
These tumors were also occasionally seen on the rib cage, in
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FIG. 2. Macroscopic pathology of Py early region transgenic mice. All photographs were of fresh tissue. (A) Left, ear of an adult Py-4
transgenic mouse; right, ear of an adult nontransgenic mouse. Note the blood-filled sacs visible in the transgenic mouse ear. Magnification,
x5. (B) Left, skull of an adult Py-4 transgenic mouse; right, skull of an adult nontransgenic mouse. Note the white raised areas on the
transgenic mouse skull and contrast these with the opalescence of the healthy skull. Magnification, x3. (C) Cystic structure from the
retroperitoneal area of an adult Py-4 transgenic mouse. Note the lack of bloody areas. Magnification, x 3. (D) Section of spine showing a tumor
in an adult Py-5 transgenic mouse. The tumor is bony and attaches to the ribs below. Magnification, x 3.
association with joints, and in the skull. On rare occasions,
mice of both lineages also developed large solid and fatty
protuberant tumors at random locations. Death was most
likely due either to hemorrhage or to wasting from paralysis
or a large tumor.
The microscopic analysis of tumor tissues is presented in
Fig. 3. Histological study of the blood-filled tumors of Py-4
mice showed small blood-filled sacs interspersed among
normal tissue structures, as shown in the photomicrograph
of a Py-4 ear (Fig. 3A). A higher magnification of this type of
tumor showed that the caverns were lined by one or a few
layers of thin, elongated cells (Fig. 3B). This histological
picture is consistent with the identification of these tumors
as vascular endothelial cell tumors, and they resemble the
hemangiomas described in Py MT mice (3).
The microscopic examination of a Py-3 bone tumor
showed tumor tissue adjacent to normal rib muscle tissue,
with no sign of invasion (Fig. 3C). Upon visual examination,
the skull thickenings of the Py-4 mice appeared multifocal
and seemed to involve more healthy bone tissue than did the
bone tumors of the Py-3 and Py-5 mice. At the microscopic
level, however, the Py-4 skull had tumors that resembled the
Py-3 bone tumor (Fig. 3D). Higher magnification of the
tumor tissue revealed individual atypical cells surrounded by
extracellular material (inset, Fig. 3D). This histology is
characteristic of osteogenic sarcomas, tumors of osteoblast
cells that produce bone matrix.
The fluid-filled cysts found in all Py-4 mice consisted of
irregular open spaces with some leukocytes and with expan-
sion of both the lining and surrounding fatty tissue (Fig. 3E).
The association of some of the cysts with sites of major
lymph nodes, and the presence of straw-colored fluid and of
leukocytes rather than erythrocytes all contribute to the
identification of these structures as lymphangiomas. The
large fatty tumors that occasionally were found in Py-3 and
Py-5 mice consisted of relatively undifferentiated cells that
appeared to be of mesenchymal origin, which is consistent
with the identification of these tumors as fibrosarcomas (Fig.
3F).
Expression analysis. To determine the expression pattern
of the transgene in the Py transgenic mice, RNA extracted
from healthy tissues and from tumors of mice of each of the
three lineages was analyzed. The Py early region transgene
(Fig. 1) can theoretically produce a primary Py transcript
that is alternatively spliced to yield different Py mRNAs
encoding different Py early region proteins, as occurs in
Py-infected cells (37). To obtain semiquantitative data on the





































FIG. 3. Microscopic pathology of Py early region transgenic mice. All tissues were fixed in 10% formalin, embedded in paraffin, sectioned,
and stained with hematoxylin and eosin. (A) Cross-section of an ear of a Py-4 transgenic mouse, showing a blood-filled sac surrounded by
healthy ear tissue. Magnification, x 184. (B) Higher magnification of a different area of the Py-4 ear shown in panel A. Note the blood-filled
sacs surrounded by a few layers of elongated endotheliumlike cells marked by arrows. Magnification, x 368. (C) Rib tumor and surrounding
tissue from an adult Py-3 transgenic mouse. The tumor was bony and attached to the rib. Note the lack of invasion into the surrounding muscle
tissue. Magnification, x 184. (D) Skull tumor of an adult Py-4 transgenic mouse. Note the deposits between the cells. Magnification, x 184.
Inset, higher magnification of bone tumor showing individual cells (marked by arrows) surrounded by deposited material. Magnification,
x 368. (E) Cystic structure from an adult Py-4 transgenic mouse. Note the irregular spaces containing some heavily stained cells and lined by
elongated cells (marked by arrows). Magnification, x368. (F) Solid tumor from an adult Py-3 transgenic mouse. Note the undifferentiated
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FIG. 4. RNA protection analysis of transgenic mouse tissues.
Total RNAs (20 ,ug except in lane 8, which contained 10 ,ug) were
isolated from mouse tissues and used in an RNA protection assay.
The products were electrophoresed in 8 M urea-5% polyacrylamide
gels and subjected to autoradiography at -80°C with an intensifying
screen. Lane 1, MT-1A (Py MT transgenic) testes; lane 2, LT-1 (Py
LT transgenic) testes; lane 3, Py T54 control cells transformed with
Py; lane 4, B6D2F1 (nontransgenic) liver; lane 5, mock reaction;
lane 6, Py-4 liver; lane 7, Py-4 testes; lane 8, Py-4 skull (with tumor)
(loading, 25% of that in other lanes); lane 9, Py-3 liver; lane 10, Py-3
testes; lane 11, Py-3 skull (with abnormal area); lane 12, Py-5 bone
(with tumor); lane 8A, same as lane 8 (Py-4 skull with tumor). Lane
8A was exposed for 18 h, and lanes 1 to 12 were exposed for 6 days.
Left margin shows fragments corresponding to protection by tran-
scripts: probe, 32P-labeled antisense RNA corresponding to a XhoI
(nucleotide 60 linker)-to-PstI (nucleotide 484) restriction fragment;
MT/ST, transgenic MT-ST transcript; LT, transgenic LT transcript;
MT/ST*, viral MT-ST transcript; LT*, viral LT transcript. Trans-
genic RNA protects a larger fragment because the RNA initiates
upstream of the major viral transcriptional start site (3). Right
margin shows size markers (in base pairs) (pBR322 digested with
HpaII).
protection assay. Our probe in this assay allowed for the
identification of a unique protected fragment for Py LT RNA
but did not distinguish among MT, ST, and unspliced RNAs.
We therefore used PCR analysis to unambiguously identify
each of the species of Py RNA.
RNA protection analysis with a PxXP64 antisense probe
revealed multiple sites of Py transgene expression in the
mice (Fig. 4 and Table 3). The major transcription initiation
site in the transgene is 5' of major viral transcription start
sites (compare controls in Fig. 4, lanes 1 to 3 [3]). Thus, the
presence of a protected band of 424 bases results from the
presence of MT, ST, and/or unspliced RNAs, while a
protected band of 349 bases results from the presence of LT
RNA. All tumors and some unaffected tissues, including the
testes of all lineages, expressed the Py transgene (Fig. 4 and
Table 3). Although the testes of Py-4 mice had multiple small
vascular hemangiomas that may have been solely responsi-
ble for transgene expression in this organ, it is likely that
there was substantial contribution from unaffected testicular
tissue, because the pattern of protected fragments (see
below) resembled that of unaffected testes and not that of
tumor tissue.
TABLE 3. Summary of expression analysis of Py transgenic mice
Results of analysis ofb:
Py RNA
Source assayed Py-4 Py-3 Py-5
fora
PRO PCR PRO PCR PRO PCR
Tumorc M + S + + + + + +
L - + - + - +
Testes M + S + + + + + +
L + + + + + +
Liver M + S + + - +
L - +/- - - - -
Spleen M + S + + - +
L - - - _ _ _
Kidney M + S + + - + - +
L - - _ _ _ _
Brain M + S - + - +
L - +/- - +1- - -
Total RNA was assayed for either Py MT and ST RNAs (M + S) or for Py
LT RNA (L) in separate experiments.
b PRO, RNA protection assay; PCR, PCR analysis. All tissues but Py-3
kidney were analyzed with at least two different tissue samples. +, positive
signal in all tissue samples; -, negative signal in all tissue samples; +/-, one
positive and one negative signal from tissues.
' Tumor represents skull osteosarcoma and lymphangioma for Py-4, he-
mangioma and fibrosarcoma for Py-3, and osteosarcoma for Py-5.
Mice of the Py-4 lineage (Fig. 4, lanes 6 to 8 and 8A, and
Table 3) had the greatest number of unaffected sites that
expressed the transgene, including the liver. In contrast,
RNAs from mice of the Py-3 lineage (Fig. 4, lanes 9 to 11,
and Table 3) did not show protected fragments indicating
liver expression of the transgene (Fig. 4, lane 9). However,
RNAs from Py-3 testes, an unaffected tissue, and an abnor-
mal Py-3 skull that probably carried a tumor were positive
for the protected fragments (Fig. 4, lanes 10 and 11). Mice of
the Py-5 lineage showed an expression pattern similar to that
of the Py-3 mice, with transgene expression restricted to
tumors and testes (Fig. 4, lane 12, and Table 3).
It was possible to determine the relative levels of Py
transgene RNA expression in a comparative manner. The
amount of total RNA, the amount of reaction mixture loaded
on the gel (see the legend to Fig. 4), and the relative intensity
of the signals showed that the level of expression in unaf-
fected testes of all lineages was approximately equivalent,
whereas the level of transgene RNA expression in tumor
tissue was substantially higher. For example, RNA from a
skull tumor of a Py-4 mouse (Fig. 4, lanes 8 and 8A, short
exposure) was used, so that lane 8 represents 15% of the
RNA in lane 7, yet the signal appears 5- to 10-fold more
intense. Thus, the overall level of transgene expression
relative to total RNA is higher in tumors than in unaffected
tissues.
The pattern of transgene expression differed among the
different sites of expression. A protected fragment corre-
sponding to Py LT RNA protection was clearly visible in
reaction mixtures of testis RNAs of mice of all lineages (Fig.
4, lanes 7 and 10, and Table 3), and this protected fragment
was not detected in reaction mixtures of tumor RNAs or
RNAs from other unaffected sites. The presence of back-
ground does not exclude the possibility that low amounts of
LT RNA are present in nontesticular RNAs, and subsequent
PCR analysis (see below) revealed LT-specific products in a
subset of these RNAs. However, RNA protection analysis
of 8 different testis RNAs and 15 tumors and positive tissues
of various lineages showed that the pattern of an LT-
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FIG. 5. PCR expression analysis of transgenic mouse tissues.
Total RNAs from mouse tissues were reverse transcribed using Px
oligonucleotide 2 as a primer (see Fig. 1 for location). The cDNAs
were subjected to PCR analysis, electrophoresed through an 8%
polyacrylamide gel, and stained with ethidium bromide. (A) PCR
analysis using Px oligonucleotides 5 and 8 as primers. Lane 1, Py-4
liver; lane 2, Py-4 testes; lane 3, Py-4 skull (with tumor); lane 4, Py-3
liver; lane 5, Py-3 testes; lane 6, Py-3 tumor (fibrosarcoma); lane 7,
Py T54 control cells transformed with Py; lane 8, B6D2F1 (nontrans-
genic) liver; lane 9, MT-1A testes; lane 10, ST-1 (Py ST transgenic)
testes; lane 11, Py-5 tail DNA used without reverse transcription.
Left margin shows size markers (in base pairs) (pBR322 digested
with HpaII). Right margin shows positions of expected PCR prod-
ucts: UNS, unspliced RNA. (B) PCR analysis using Px oligonucle-
otides 2 and 3 as primers. Lanes 1 to 8, as described for panel A;
lane 9, LT-1 pituitary tumor. Left margin shows size markers (in
base pairs) (pBR322 digested with HpaII). Right margin shows
positions of expected PCR products.
protected fragment only in testis RNA is consistent (data not
shown). The relative ratio of the different Py RNAs thus
seems to be regulated differently in testes than in tumors and
other tissue sites of expression.
To determine the exact pattern of expression of each of
the Py RNAs, we employed a sensitive PCR assay to cDNAs
synthesized from RNAs of various tumors and tissues. One
set of primers (oligonucleotides Px5 and Px8; see Fig. 1 for
locations) gives PCR products unique to templates for un-
spliced, MT, and ST RNAs, and a second set of primers
(oligonucleotides Px2 and Px3; see Fig. 1 for locations)
allowed for detection of a PCR product specific to LT RNA.
The results of the PCR are shown in Fig. 5. Lanes 1 to 5 of
the PCR analysis are the same RNA samples as were
analyzed by RNA protection in lanes 6 to 10 of Fig. 4.
Analysis of Py MT and ST RNAs (Fig. 5A) revealed that all
sites of transgene expression were positive for PCR products
of 189 and 175 bp that were specific to ST and MT RNA,
respectively. An additional prominent PCR product of 238
bp could result from an unspliced RNA template, or it could
result from DNA contamination of the RNA samples. It was
determined that approximately 50% of the 238-bp PCR
product resulted from a template that is destroyed by alka-
line conditions (data not shown), indicating that unspliced
RNA and contaminating DNA both contribute templates to
this product. This finding is consistent with the results of
RNA protection analysis with a probe that covers the MT
and ST splice sites and gives a unique protected fragment
with unspliced RNA. In this analysis, more than 90% of the
"unspliced" protected fragment was alkaline sensitive, and
the relative amount of this fragment did not vary among
different RNAs (data not shown).
LT RNA analysis (Fig. SB) showed that a subset of tissues
and all tumors was positive for an LT RNA-specific PCR
product of 414 bp. All testes that showed an LT RNA-
specific protected fragment by RNA protection analysis
produced the LT-specific PCR product (Fig. SB, lanes 2 and
5, and Table 3). The tumors and Py-4 liver, however, did not
have detectable LT-specific protected fragments by RNA
protection, yet they also produced an LT-specific PCR
product. This discrepancy probably results from the high
sensitivity of the PCR reaction and the lack of background in
this assay. The PCR reaction was not quantitated, so abso-
lute amounts of LT RNA were not determined, but it is likely
that Py transgenic-mouse tumors contain very low but
detectable levels of LT RNA.
The expression analysis using both assays was extended
to other tissues, and the results are documented in Table 3.
Several results were confirmed and extended by this com-
plete analysis. First, as noted above, all tumors and testes
from mice of all lineages expressed the Py transgene. Sec-
ond, other unaffected organs were sites of transgene expres-
sion in a lineage-dependent manner. For example, Py-4 mice
showed transgene expression in the liver, spleen, kidney,
and brain, and Py-5 mice showed expression only in the
kidney. Third, some sites of expression, such as brain
tissues of Py-4 and Py-3 mice, were negative by RNA
protection analysis but positive by the more sensitive PCR
analysis. Finally, expression of the LT RNA was not detect-
able in some sites where expression of ST and MT RNAs
was documented, such as spleens and kidneys of Py-4 mice.
It thus appears that both lineage-specific differences in
expression patterns and tissue-specific differences in the
relative amounts of the different Py mRNAs contribute to a
complex expression pattern of the Py early region transgene.
DISCUSSION
The analysis of these transgenic mice shows that the Py
early region is tumorigenic in transgenic mice. Five members
(62.5%) of a group of eight founder mice had detectable
pathology that was fatal to the animals in all cases. Three
lineages of Py transgenic mice were established in which the
Py early region transgene was passed through the germ line
to progeny. All mice that carried the transgene developed
fatal tumors. Mice of all lineages developed vascular and
bone tumors, indicating that this tissue specificity for Py
transgene action is a result of the cis-acting sequences
associated with the transgene.
The tumors induced by the Py transgene are found exclu-
sively in tissues of mesenchymal origin. In addition to the
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vascular and bone tumors, the lymphangiomas and fibrosar-
comas that were scored are also mesenchymal tumors. No
evidence of epithelial tumors was seen, and the common
parotid tumor induced by viral infection was not scored in
any Py transgenic mice. The reason for this restricted tumor
spectrum in the transgenic mice is not known, and it may
reflect either the tumor spectrum of the Py strain from which
the transgene is derived or the specific properties of the
transgene construct.
The Py transgene was derived from the Al strain of Py.
and the tumor spectrum of this strain has not been charac-
terized. The Al genome closely resembles that of the A2
strain of Py in the noncoding region (3, 30), but the entire
genome has not been sequenced. The tumor spectrum of the
Py transgene is remarkably similar to the tumor spectra of
two strains of Py, A3 and RA, that produce only mesenchy-
mal tumors; it is not similar to the spectra of two other Py
strains, A2 and PTA, that produce both mesenchymal and
epithelial tumors (4, 10, 16). The noncoding regions of the
different Py genomes were found to influence the frequency
of tumor formation, but the primary determinant of tissue
tropism for viral tumorigenesis was localized to a single
amino acid polymorphism in the VP1 capsid protein encoded
by the late region (14).
The late region of the Py transgene carries a large deletion
that includes this polymorphic codon, so this primary deter-
minant of viral tumor tropism is presumably not expressed in
Py transgenic mice. Therefore, the mesenchymal specificity
of both the Py transgene and the RA and A3 Py strains may
result from the absence of a dominant determinant in the late
region that results in epithelial tumors. This hypothesis is
supported by coinfection experiments showing that the
expanded tumor spectrum is dominant over the restricted
mesenchymal-only tumor spectrum (10). It is notable, how-
ever, that although the Py transgene shares with the RA and
A3 strains a mesenchymal-tumor spectrum, it does not share
a weakly oncogenic phenotype. Rather, the Py transgene is
highly oncogenic, inducing tumors with 100% penetrance
and with fatality as early as 11 to 12 weeks of age.
The mechanism responsible for the different tropisms of
the Py strains is not elucidated but seems to involve inter-
actions with cell surface receptors, because both viral repli-
cation patterns in mouse organs and cell surface properties
correlate with the different tumor spectra (12, 15). However,
the Py transgene does not require cell entry yet shows a
mesenchymal cell specificity in its action. This result sug-
gests that virus entry, while necessary, is not sufficient to
confer epithelial tropism. There appears to be an additional
intracellular requirement for epithelial tropism that is lacking
in the Py transgene. Further evidence for this requirement is
that the Py virus tumor spectrum in nulnu nude mice is a
subset of the persistently infected tissues (11).
Although the Py transgene has a restricted tumor spec-
trum relative to that of Py infection by some strains, the
finding of tumors in multiple tissues of transgenic mice is an
expanded tumor spectrum relative to that of Py MT trans-
genic mice, which develop only vascular hemangiomas (3),
and Py LT mice, which develop only pituitary tumors (2, 2a).
The Py transgenic mice do not live long enough to develop
the overt pituitary tumors of the Py LT mice, and the lack of
vascular and bone pathology in the Py LT mice suggests that
the Py MT oncogene is required for tumorigenesis at these
sites.
An explanation of the lack of bone pathology in the Py MT
mice is less obvious. The Py transgene and the Py MT
transgene are colinear except for the presence of 63 bp of
MT intron sequences that are missing in the Py MT cDNA.
Possible reasons for the difference in tumor spectrums are (i)
that the presence of the Py LT and/or ST gene products is
required for tumorigenesis in bone and (ii) that the presence
of the MT intron sequences leads to expression in bone or to
increased levels of expression in general. Evidence to sup-
port the latter hypothesis is that when triply transgenic mice
carrying all three Py transgene cDNAs were bred from
preexisting transgenic mice, these triply transgenic mice did
not develop detectable bone pathology (41). However, we
have not detected gross differences in expression levels
between the Py early region transgene and the Py cDNA
transgenes in either tumors or unaffected tissue, and the
expression of the Py transgene was not detected in unper-
turbed skull tissue of Py-3 and Py-5 mice (41). Therefore, if
differences in site or expression levels are responsible for the
expanded tumor spectrum of the Py transgene, the alter-
ations are subtle enough to have escaped detection thus far.
The Py early region transgene was expressed in the tumors
that developed as well as in some unaffected organs. The
major site of expression was the testis, and all testes of males
of all lineages expressed the Py transgene. Other nontumor
sites of expression, such as the liver, spleen, kidney, and
brain, varied with lineage. Thus, mice of the Py-4 lineage
showed the broadest spectrum of tissues expressing the
transgene, and they also developed the most severe pathol-
ogy and died at a very young age. It is likely, therefore, that
the Py-4 transgene integrated in a chromosomal site that
promotes widespread expression early in life, whereas the
Py-3 and Py-5 integrations may have occurred in a chromo-
somal context that is more restrictive of expression. These
differences in expression of the same transgene among
different lineages have been documented, and they some-
times reflect temporal patterns of tumorigenesis (20, 40).
The Py early region transgene can produce three different
mRNAs by alternative splicing, and these RNAs encode the
three early region proteins Py LT, MT, and ST (37). Differ-
ences in the relative amounts of the three RNAs were found
in transgenic mouse tissues, and specifically, the relative
amount of Py LT RNA was higher in testes than in all other
sites of expression. This finding suggests that regulation is at
the level of alternative splicing, although it is formally
possible that differential RNA stability leads to higher rela-
tive levels of Py LT RNA in testes. Splicing of Py LT RNA,
which has a unique 5' donor site and a 3' acceptor site
common to Py ST, thus appears to be favored in testes
relative to other sites of expression. In contrast, the coex-
pression of Py MT and ST at all expression sites is consistent
with the reported cooperativity between the two different 3'
acceptor sites in vitro (18). Other alternatively spliced genes
such as that for calcitonin-CGRP show a tissue-regulated
splicing pattern that is reconstituted in transgenic mice (8).
Regardless of how differential expression is effected, the
low levels of Py LT RNA (detectable only by PCR) that are
present in tumor RNAs suggests that high levels of Py LT
RNA are not required for tumorigenesis in Py transgenic
mice. In contrast, the presence of all three Py early region
mRNAs in the testes suggests that coexpression of all early
region gene products is not sufficient for tumorigenesis in the
testes and that other events or conditions are required for
Py-mediated tumorigenesis. This hypothesis is supported by
the finding that the testes of Py-4 mice express the early
region proteins as well as the RNAs (18a).
Analysis of Py early region transgenic mice has docu-
mented that Py-mediated tumorigenesis in mesenchymal
tissues does not require the viral life cycle and virus repli-
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cation. Moreover, these mesenchymal sites of tumor forma-
tion in transgenic mice do not require high levels of Py LT
RNA for tumor formation. Yet other sites of transgene
expression elaborate the full complement of early region
proteins and do not form tumors, suggesting that other
events are required for testicular tumorigenesis. Taken to-
gether, these results show that the mechanisms of viral
pathogenesis are influenced by tissue specificity in the ef-
fects of the Py early region gene products. Further analysis
of tissue-specific differences in tumor susceptibility of Py
transgenic mice may further elucidate the mechanisms of
tumorigenesis.
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